A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPGEYER, C. E.LOIBL, S.MAMOUNAS, E. P.UNTCH, M.WOLMARK, N.HUANG, C-SMANO, M.ZHENG, M.SMITT, M.MINCKWITZ, G. von2016-11-222016-11-222013CANCER RESEARCH, v.73, suppl.24, 20130008-5472https://observatorio.fm.usp.br/handle/OPI/16651engrestrictedAccessA phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)conferenceObjectCopyright AMER ASSOC CANCER RESEARCH10.1158/0008-5472.SABCS13-OT1-1-06Oncology1538-7445